Ge Long Hui A P P·2025-10-14 09:06Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanguo, has received notification from the National Medical Products Administration (NMPA) regarding the withdrawal of the registration application for the drug Dihydrosuccinimide Ruxolitinib capsules, which is intended for the treatment of non-small cell lung cancer (ALK+ and ROS1+) [1] Group 1 - The new drug is an innovative small molecule chemical drug primarily aimed at treating non-small cell lung cancer [1] - The registration application for the drug was accepted by the NMPA in March 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients who are positive for anaplastic lymphoma kinase (ALK) [1] - The withdrawal of the registration application does not signify the termination of the project; Fosun Wanguo plans to enhance the registration materials according to the latest technical requirements from the NMPA and will resubmit the application as soon as possible [1]